Sonitus Continues Climb Toward Reimbursement With Series D
This article was originally published in Start Up
Early last year, Sonitus Medical obtained 510(k) notification for its non-surgical hearing assistance device to be used in patients with single-sided deafness. The culmination of five years of work, the FDA clearance positioned Sonitus to compete in, and company officials hope ultimately to expand, the $100 million market for devices for conductive hearing loss. But to do that effectively, the company still needs to convince Centers for Medicaid and Medicare Services and private payors.
You may also be interested in...
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?
Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals
Commissioner expresses concern about agency lawyers leaving and then representing US FDA’s opponents in court. Also, as lawsuits about abortion pill continue, Kaiser Family Foundation finds the public trusts FDA more than the judiciary on determining products’ safety and effectiveness.